Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 15

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 15
---
 the Promissory Notes, the exercise price and number of Common Shares exercisable under the January 2024 PIPE Warrants was adjusted in accordance with the terms of such warrants, and on November 26, 2025 and on December 3, 2025, in connection with the Fourth November 2025 Offering and the December 2025 Offering, respectively, the exercise price and number of Common Shares exercisable under the January 2024 PIPE Warrants was further adjusted in accordance with the terms of such warrants. As a result of such adjustment, the January 2024 PIPE Warrants are now exercisable for an additional 12,545,230 Common Shares, or Additional Warrant Shares, beyond the 1,126,480 Common Shares exercisable thereunder immediately prior to the adjustments. On November 14, 2024, 393,790 January 2024 Warrants were exercised for $78,750, and 1,979,110 January 2024 warrants were exercised on a cashless basis, for which 1,175,328 Common Shares were issued. In connection with the January 2024 Private Placement, the selling shareholders named in this prospectus may offer and sell up to an aggregate of 12,545,230 Common Shares issuable upon exercise of the Additional Warrant Shares underlying the January 2024 PIPE Warrants. 10 Implications of Being an “Emerging Growth Company” and a Foreign Private Issuer Emerging Growth Company We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not “emerging growth companies” such as not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. We could remain an “emerging growth company” for up to five years, which will be December 31, 2027, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenue exceeds $1.235 billion, (b) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the